Price Watch

ICER Analysis Points out Novartis Mayzent Too High

ICER Analysis Points out Novartis Mayzent Too High

ICER found that tiprotimod (Mayzent) reduced the risk of multiple sclerosis progression as well as decreased inflammatory disease activities however it’s analysis reveals the drug is priced too high for the market. The Institute for Clinical and Economic Review...

FDA Approves Pfizer’s Biosimilar, Zirabev, to Roche’s Avastin

FDA Approves Pfizer’s Biosimilar, Zirabev, to Roche’s Avastin

The FDA has approved bevacizumab-bvxr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin, Genentech/Roche), for the treatment of five types of cancer. These cancers include metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic...

subscribe

CNS Summit
subscribe

Pin It on Pinterest